Study of Relacorilant in Combination With Nab-Paclitaxel in Patients With Metastatic Pancreatic Ductal Adenocarcinoma

PHASE3

Phase

TERMINATED

Status

Enrollment

INDUSTRY

Sponsor class

Stopped The independent data monitoring committee found no safety issues, however the observed response rate did not meet the predefined threshold for continuing the study. The study was terminated by the Sponsor.

Conditions

Metastatic Pancreatic Ductal Adenocarcinoma

Interventions

DRUG: Relacorilant, 100 mg and 25 mg
DRUG: Nab-paclitaxel

Sponsor

Corcept Therapeutics